Early data

Early data

Obesity
Company Product
7TM TM30338 synthetic analog of human hormones PYY3-36 and pancreatic polypeptide
Diet-induced obese (DIO) animals: TM30338 showed superior long-term reduction in body weight vs. PYY3-36 alone
Alizyme/ Takeda Cetilistat lipase inhibitor
Prelim Ph IIb data in 612 obesity pts: 80 and 120 mg cetilistat and 120 mg thrice-daily Xenical led to weight reduction of 3.85, 4.32 and 3.78 kg at 12 weeks, respectively, vs. 2.86 kg with placebo (p=0.01, p=0.0002 and p=0.008). Also, fewer patients given cetilistat discontinued treatment due to adverse events (2.5% for 40 mg, 5% for 80 mg and 2.5% for 120 mg) compared with placebo (6.4%) or Xenical (11.6%). Xenical is marketed by Roche

Read the full 1135 word article

How to gain access

Continue reading with a
two-week free trial.